Envisagenics focus is on harnessing RNA for therapeutics. Splicing is a natural biological process that converts premature mRNA into mature mRNA by removing non-coding sequences. There can be various outcomes of splicing, some of which are linked with disease - to address this, Envisagenics built their SpliceCore® software platform that leverages RNA sequencing and AI algorithms to identify, test and validate drug targets with speed and precision. A unique aspect of the platform is that besides identifying new targets for RNA therapeutics, Envisagenics can learn about the mechanism of action by which their antisense drugs regulate splicing events. This leads to more transparent and verifiable AI predictions. Envisagenics pipeline is currently in preclinical stages with their lead program for breast cancer.

Envisagenics

Founded: 2015
Location: New York, NY
Employee range: 11 - 50
Funding: $2M grant Aug 2022; $300k grant Oct 2019

Short description:

Drug notes:

Long description:

Jobs: